Back

Early use of roxadustat in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: a randomised clinical trial

30 August 2026 (13:25 - 13:35)
Organised by: Logo
Congress Presentation Part of: Primary percutaneous coronary intervention in STEMI: new strategies to improve reperfusion and outcomes ST-Elevation Myocardial Infarction (STEMI) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Yueying Wang

Rui Jin Hospital- Shanghai Jiaotong University School of Medicine, Shanghai (China)

5 More presentations in this session

Presentation thumbnail
Clinical study on the efficacy and safety of ketotifen in STEMI patients undergoing primary PCI
Mr P. Xie (Beijing, CN)
Abstract
Presentation thumbnail
Timing matters: impact of early oral p2y12 pretreatment on ischemic outcomes and reperfusion in stemi patients undergoing primary pci
Mr A. Gasca (Cali, CO)
Abstract
Presentation thumbnail
Bivalirudin versus heparin in high and low bleeding risk patients undergoing primary PCI for STEMI: pre-specified analysis from the BRIGHT-4 trial
Professor M. Qiu (Shenyang, CN)
Abstract
Presentation thumbnail
Immediate versus staged complete revascularization in ST-segment elevation myocardial infarction and multivessel disease with complex coronary anatomy: Insights from the OPTION-STEMI trial
Professor M. Kim (Gwangju, KR)
Abstract
Presentation thumbnail
Pre-reperfusion dapagliflozin does not reduce infarct size in STt-elevation myocardial infarction: a randomized controlled trial
Assistant Professor K. Leemasawat (Chiang Mai, TH)
Abstract

Access the full session

Session thumbnail
Primary percutaneous coronary intervention in STEMI: new strategies to improve reperfusion and outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 13:25 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of early intravenous landiolol, an ultrashort-acting beta-blocker on infarct size and its safety in patients with myocardial infarction undergoing primary PCI: a randomized, controlled study
28 August 2020
thumbnail
Congress Presentation
The prolyl-hydroxylase inhibitior Roxadustat upregulates HIF-1alpha and is associated with improved cardiac repair after myocardial infarction in mice
25 August 2023
thumbnail
Congress Presentation
Vitamin D supplements do not affect adverse left ventricular remodelling after an anterior myocardial infarction
1 September 2025
thumbnail
Congress Presentation
Blood-based transcriptional signatures at hospital admission are associated with cardiac magnetic resonance markers of STEMI prognosis
12 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources